MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Pluristem Therapeutics Operating Income 2011-2026 | PSTI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Pluristem Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.2 M | -22.2 M | -27.2 M | -41.6 M | -50.6 M | -29.5 M | -35.5 M | -33.7 M | -28 M | -23.3 M | -25.3 M | -27.8 M | -22.2 M | -15 M | -11.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.1 M | -50.6 M | -27.7 M |
Quarterly Operating Income Pluristem Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.51 M | -6.35 M | - | -5.4 M | -4.96 M | -5.2 M | - | -5.53 M | -5.21 M | -5.38 M | - | -7.1 M | -6.68 M | -6.92 M | -13.6 M | -10.5 M | -10.8 M | -11.4 M | -22.2 M | -14.2 M | -13.1 M | -8.74 M | -13.1 M | -8.74 M | -6.37 M | -7.2 M | -6.37 M | -7.2 M | -8.33 M | -8.97 M | - | -9.05 M | -8.47 M | -7.44 M | -8.47 M | -7.44 M | -6.65 M | -6.56 M | -6.65 M | -6.56 M | -4.23 M | -5.52 M | -4.23 M | -5.52 M | -6.3 M | -5.62 M | -6.3 M | -5.62 M | -6.99 M | -4.86 M | -6.99 M | -4.86 M | -4.88 M | -4.19 M | -4.88 K | -4.19 M | -2.12 K | -4.33 M | -2.12 M | -4.33 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.12 K | -22.2 M | -7.04 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
509 B | $ 18.06 | - | $ 28.2 B |  Japan |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 19.44 | -0.46 % | $ 909 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Protara Therapeutics
TARA
|
-64.5 M | $ 5.03 | -3.08 % | $ 215 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-71 M | $ 67.0 | -0.3 % | $ 2.8 B | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Theravance Biopharma
TBPH
|
20 M | $ 14.9 | -1.91 % | $ 750 M |  Cayman-islands |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.2 | -6.97 % | $ 306 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B | Cayman-islands |
 |
Bio-Techne Corporation
TECH
|
102 M | $ 51.31 | -2.65 % | $ 8.08 B | USA |
 |
Tenax Therapeutics
TENX
|
-56.4 M | $ 14.64 | -2.2 % | $ 574 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-15.9 M | $ 1.07 | -2.29 % | $ 21.9 M | Israel |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
2.16 B | $ 28.76 | -3.43 % | $ 32.9 B | Israel |
 |
Enochian Biosciences
ENOB
|
-189 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-23.6 M | $ 2.03 | -1.46 % | $ 116 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-844 K | $ 23.81 | 1.51 % | $ 641 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 46.38 | -2.45 % | $ 4.17 B |  Schweiz |